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Purpose 
National monitoring of variation in the quality of infection control in paediatric intensive care 
units (PICUs) requires comparisons of risk-adjusted rates. To inform the development of a 
national monitoring system, we evaluated the effects of risk-adjustment and outcome 
definition on comparisons of blood-stream infection (BSI) rates in PICU, using linkage of 
risk-factor data captured by national audit (PICANet) with laboratory records of BSI.  
 
Methods  
Admission data for two children’s hospitals 2003-2010 were extracted from PICANet and 
linked using multiple identifiers with laboratory BSI records. We calculated trends of PICU-
acquired BSI, defined as BSI occurring between >=2 days after admission until <=2 days 
following discharge. In one PICU, we compared rates of all PICU-acquired BSI with 
clinically significant PICU-acquired BSI submitted to the national surveillance system. 
 
Results 
1428 (6.8%) of 20,924 admissions were linked to 1761 PICU-acquired BSI episodes.  The 
crude incidence rate-ratio for PICU-acquired BSI between PICUs was 1.15 (95% confidence 
interval (CI) 1.05-1.26) but increased to 1.26 (1.14-1.39) after risk-adjustment. Rates of 
PICU-acquired BSI were 13.44 (95% CI 12.60-14.28) per 1000 bed-days at PICU 1 and 
18.05 (95% CI 16.80-19.32) at PICU 2. Of PICU-acquired BSI at PICU 2, 41% was 
classified as clinically significant. Rates of PICU-acquired BSI decreased by 10% per year 
between 2003-2010 for skin organisms and 8% for non-skin organisms. 
 
Conclusions 
Risk-adjustment and standardisation of outcome measures are essential for fair comparisons 
of BSI rates between PICUs. Linkage of risk-factor data and BSI surveillance is feasible and 
could allow national risk-adjusted monitoring.  
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INTRODUCTION 
Healthcare-associated infection (HAI) is an important cause of adverse clinical outcome and 
cost to the UK National Health Service (NHS), and paediatric intensive care units (PICUs) 
have one of the highest reported rates of nosocomial blood-stream infection (BSI) of any 
clinical specialty [1-4]. Interventions aimed at reducing HAI have succeeded in dramatically 
decreasing rates of infection in the US and have led the way for similar interventions in the 
UK, including the introduction of the Department of Health Saving Lives CVC care bundle in 
2005 [5-8]. 
Monitoring of infection outcomes is vital for determining the impact of these interventions 
and for sustaining improvements in practice [9,10].  Comparison of healthcare associated BSI 
rates and assessment of variation of quality of care between PICUs would allow improved 
practices to be targeted at those most likely to benefit.  
Reliable risk-adjustment is required for meaningful comparisons between PICUs [11]. At a 
national level, no single dataset accurately captures both clinical and microbiological BSI 
data [12]. Labbase2 is a national voluntary microbiological surveillance database collated by 
the Health Protection Agency (HPA), based on clinically significant isolates identified at 
laboratories serving NHS hospitals [13]. The Paediatric Intensive Care Audit Network 
(PICANet) collects data on all children admitted to PICUs in Britain, including clinical 
details such as diagnosis and morbidity score on admission [14]. Linkage of these existing 
datasets offers an efficient method for providing risk-adjusted national surveillance.  
To demonstrate the effect of risk-adjustment using routinely collected data and the 
importance of standardised outcome measures, we linked PICANet data with microbiology 
data from two large UK PICUs, to assess reductions in BSI acquired within PICU.  
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METHODS 
Data and case definition 
Admission data for all children admitted to Birmingham Children’s hospital (BCH) PICU 
(General and Cardiac) and Great Ormond Street Hospital (GOSH) PICU (General and 
Cardiac) between March 2003 and December 2010 were extracted from the PICANet 
database. Variables extracted for analysis were admission and discharge dates, Paediatric 
Index of Mortality (PIM2) score at admission, age, sex, admission type (planned or 
unplanned), admission source (same hospital or elsewhere), primary diagnosis at admission 
(based on primary diagnosis coded with the International Classification of Disease (ICD10)), 
and variables indicating renal support and mechanical ventilation [15]. 
BCH and GOSH laboratories routinely record microbiology data for all bacterial isolates 
from blood culture. From these laboratory systems, we extracted data on all positive isolates 
for children admitted to hospital between March 2003-2010, regardless of whether they were 
considered contaminants or clinically significant.  
We defined an episode of BSI as any positive blood culture with: 
1. One or more organisms isolated from any blood sample taken on the same day 
2. Repeated samples with positive cultures of the same organism within 14 days  
A child could have more than one BSI episode during an admission if different organisms 
were isolated on different days, or if the same organism was isolated on more than one day 
(>14 days apart).  
We defined PICU-acquired BSI as any BSI from samples taken up to two days after 
discharge from PICU, but excluding samples taken on the day of admission or the day after 
admission to PICU. As laboratory records included the date but not the time the specimen 
was taken, some included samples may have been taken between 24 and 48 hours after 
admission to PICU, thereby possibly resulting in a slight overestimation of rates. Laboratory 
data after discharge from PICU was available for the majority of children (81%) as they were 
discharged to another ward within the same hospital.  
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We separately analysed PICU-acquired BSI due to skin and non-skin organisms, as we 
hypothesised that infection control practices might have more impact on BSI due to skin 
organisms, which can be acquired during invasive procedures or sample contamination 
[16,17]. Skin organisms were defined as coagulase negative staphylococcus, Staphylococcus 
epidermidis, Corynebacterium spp. or Proprionibacterium spp.. All other organisms were 
classified as non-skin organisms. PICU-acquired BSI episodes could include either skin 
organisms, non-skin organisms, or both, and so the number of episodes of PICU-acquired 
BSI due to skin organisms and due to non-skin organisms does not add up to the total number 
of episodes. We separately analysed PICU-acquired BSI in children staying >=48 hours to 
account for any differences in the number of very short-term admissions (with a lower risk of 
infection) between PICUs.  
We assessed the effect of different case definitions for BSI reporting. The national voluntary 
surveillance system LabBase2, coordinated by the Health Protection Agency (HPA), requires 
reporting of clinically significant BSI. At one of the two laboratories, an additional variable 
indicated positive BSI that had been considered to be clinically significant and were reported 
to LabBase2, based on prospectively recorded consultant microbiologist opinion following 
regular meetings with the clinical team. At the other laboratory no classification of clinically 
significant BSI was available.  
 
Data linkage  
We generated our dataset by deterministic linkage of PICANet and microbiology records 
based on unique identifiers (NHS number, hospital number, name, date of birth and sex). 
Linkage was manually verified to ensure there were no false matches or missed matches.  
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Statistical analysis 
PICU-acquired BSI rates were calculated as the number of PICU-acquired BSI per 1000 bed-
days. Due to the low event rate, we assumed a log-linear trend and fitted Poisson regression 
models1 to the data, with length of stay (in hours) as the exposure variable. Model fits were 
compared using Akaike’s Information Criterion, goodness of fit tests and likelihood-ratio 
tests for nested models. Models with best-fit were used to identify significant risk-factors for 
PICU-acquired BSI from the patient characteristics extracted from PICANet (Table 1). For 
these models, the quarter-year of admission, age in months, and PIM2 score were treated as 
continuous variables. Quarter of year (3-month calendar period), sex, admission type, 
admission source, renal support, mechanical ventilation and diagnosis group (cardiovascular, 
respiratory, infection or other) were categorical variables. We aimed to evaluate how 
relatively simple risk-adjustment affects comparative measures rather than to inform direct 
comparisons between PICUs, as BSI risk-factors were limited within our data. A PICU-year 
interaction term was added to the model to test for differences in trends between PICUs. The 
two PICUs were randomly coded as PICU 1 and PICU 2 so that individual units were not 
identified (same coding used throughout analysis) and to deter erroneous conclusions about 
relative performance.  
Incidence rate ratios (IRR) with 95% confidence intervals (CI) were derived from models of 
best fit and used to compare rates between PICUs. Risk-adjusted rates were derived for each 
PICU by adjusting for all risk-factors found to be significant in the Poisson regression. 
Kernel density estimates of rates were estimated for graphical display.  
The time to infection was calculated as the number of days between admission and the date of 
PICU-acquired BSI. Cox proportional hazards models were fitted to the data to estimate the 
survival function for each PICU and to identify significant risk-factors for time to infection.  
Analysis was performed using Stata 11 [18]. 
 
                                                          
1 Full model: log(infections) = β1 × quarter-year of admission + β2 × PICU + β3 × admission type + β4 × 
diagnosis group + β5 × renal support + β6 × sex + β7 × age + β8 × PIM2 + β9 × admission source + β10 × 
mechanical ventilation + β11 × quarter of year + log(length of stay) 
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RESULTS 
13,376 records of bacterial isolates from blood culture dating between March 2003 and 
December 2010 inclusive were extracted from the microbiology systems at the two hospitals 
(n=5,589 PICU 1, n=7,787 PICU 2; hospital-wide). These corresponded to 6,842 episodes of 
BSI as defined in the case definition (hospital-wide). 
Records for 20,924 admissions were extracted from the PICANet database for the two PICUs 
over the same time period, comprising a total of 117,800 bed days (approximately 15,000 
bed-days or 2,600 admissions per year at the two PICUs combined). Table 1 shows the 
characteristics of the children admitted to the two PICUs between 2003-2010.  
Table 1: PICANet data: characteristics of all children admitted to two PICUs in England, 2003-2010 
Fig. 1 Probability of remaining free from PICU-acquired BSI in first 60 days of admission by PICU, 
adjusted for mechanical ventilation, age, PIM2, renal status, admission type, admission source, diagnosis 
group and quarter-year at admission. 
 
PICU-acquired BSI 
A total of 1,761 PICU-acquired BSI episodes were linked to 1,428 admissions. 144 (8.2%) of 
these BSI episodes included more than one type of organism isolated on the same day. 220 
(15%) of these admissions had multiple PICU-acquired BSI episodes during their stay in 
PICU.  
The rate of PICU-acquired BSI per 1000 bed-days was 15.17 (14.45-15.86) per 1000 bed-
days (Table 2). Quarter-year of admission, quarter of calendar year, age, admission type, 
admission source, renal support, PICU and diagnosis group were found to be significant at 
the 5% level, but there was no evidence of an effect of sex, mechanical ventilation or PIM2 
score on the rate of PICU-acquired BSI.  
The crude IRR underestimated the difference between PICUs (1.15; 95% CI 1.05-1.26) and 
the IRR increased to 1.26 (95% CI 1.14-1.39) after adjusting for differences in significant 
risk-factors between PICUs. Although the median length of stay differed by PICU (70 and 48 
hours in PICUs 1 and 2 respectively), the exclusion of short term admissions (<48 hours, n 
episodes=119) did not account for the difference between PICUs. The adjusted PICU IRR for 
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admissions >=48 hours was 1.20 (95% CI 1.08-1.33). The median time to PICU-acquired 
infection was 7 days from admission (95% binomial CI 6-7). For any given time point, a 
greater proportion of children in PICU 2 had PICU-acquired BSI than   in PICU 1, after 
adjusting for significant risk-factors (mechanical ventilation, age, PIM2, renal status, 
admission type, admission source, diagnosis group and quarter-year at admission (Figure 1)). 
Rates were lower in summer months.  
The rate of PICU-acquired BSI decreased by 9% (95% CI 7%-11%) each year during the 
study period. This corresponded to a 44% reduction (a reduction of 7.54 per 1000 bed-days) 
in the rate of PICU-acquired BSI between 2003-2010. The percentage of admissions each 
year with PICU-acquired BSI decreased by 45% over the study period (from 8.3%-4.5% of 
admissions). There was no evidence of a difference in trends between PICUs (p-value=0.43 
for trend-PICU interaction).  
Table 2: Rate and risk-adjusted incidence rate ratios for PICU-acquired BSI. Incidence rate ratio for 
year of admission converted from IRR for quarter-year of admission 
 
Skin organisms and Non-skin organisms  
The rate of PICU-acquired BSI due to skin organisms was higher than the rate of PICU-
acquired BSI due to non-skin organisms, and risk-factors for skin organisms differed to those 
for non-skin organisms (Table 3).  
Rates of PICU-acquired BSI due to both skin organisms and due to non-skin organisms 
decreased between 2003-2010. As expected, there was a larger reduction seen in PICU-
acquired BSI due to skin organisms (a 47% reduction of 5.00 per 1000 bed-days) compared 
with the decline due to non-skin organisms (a 34% reduction of 2.64 per 1000 bed-days). The 
percentage of admissions per year with PICU-acquired BSI due to skin organisms decreased 
by 52% (from 5.8-2.81) compared with 41% (from 3.6 to 2.1) due to non-skin organisms. 
The difference between PICUs was due to differences in rates of non-skin organisms - there 
was no evidence of a difference in rates of skin organisms between PICUs (IRR = 1.10; 95% 
CI 0.97-1.25). The crude IRR for non-skin organisms underestimated the difference between 
PICUs (1.38; 95% CI 1.21-1.57), rising to 1.62 (95% CI 1.41-1.85) after adjusting for 
9 
 
differences in population at risk between PICUs. Figure 3 shows the risk-adjusted rate of 
PICU-acquired BSI due to skin organisms and non-skin organisms in each PICU. 
Fig. 2 Rates of PICU-acquired BSI due to skin organisms and non-skin organisms by PICU and quarter-
year at admission, adjusted for quarter of year, admission type, admission source, age, renal support, 
diagnosis group . Symbols = Quarterly crude rates; Lines=Kernel density estimate of risk-adjusted trends 
Table 3: Rates and risk-adjusted incidence rate ratios of PICU-acquired BSI due to skin organisms and 
non-skin organisms 
 
 
Clinically significant BSI 
Classification of BSI as clinically significant or not, based on prospectively recorded clinical 
opinion, was available for PICU 2. Of the 785 PICU-acquired BSI in this PICU, 321 (41%) 
were classified as clinically significant. This was largely due the number of coagulase 
negative staphylococcus classified as not clinically significant - of the 445 PICU-acquired 
BSI due to skin organisms, only 155 (34.5%) were clinically significant. However, a 
reduction in the number of non-skin organisms was also seen – of the 419 PICU-acquired 
BSI due to non-skin organisms, 284 (67.8%) were clinically significant.   
The rate of clinically significant BSI was 7.39 (95% CI 6.58-8.18) per 1000 bed-days, 
compared with an overall rate of 18.05 (95% CI 16.80-19.32) for all PICU-acquired BSI at 
PICU 2 and 13.44 (95% CI 12.60-14.28) at PICU 1.  
Figure 3 shows the rate of clinically significant and overall PICU-acquired BSI at PICU 2.  
Fig. 3 Rates of clinically significant and all PICU-acquired BSI at PICU 2 by quarter-year at admission, 
adjusted for quarter of year, admission type, admission source, age, renal support and diagnosis group. 
Symbols = Quarterly crude rates; Lines=Kernel density estimate of risk-adjusted rates 
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DISCUSSION 
Our study demonstrates the importance of risk-adjustment and standardised outcome 
measures for monitoring of changes in BSI rates within and between PICUs. We show that 
simple risk-adjustment can be achieved through linkage of routinely collected data. As 
variation between units is a key measure for monitoring the quality of care in PICU, these 
potential sources of bias need to be taken into account to ensure fair and accurate assessment 
of variation in outcomes [19]. 
This study spans a period when national and local guidance led to major changes in infection 
control and a near halving in rates of BSI. The dramatic reduction in PICU-acquired BSI rates 
seen from 2007, particularly in BSI due to skin organisms, corresponds to the introduction of 
the Saving Lives CVC care bundle [8]. These guidelines for insertion and maintenance of 
CVCs to prevent BSI led to the introduction of 2% chlorhexidine swabs at GOSH and 
infection control audits of hand hygiene and high impact interventions consistently scoring 
>90% in BCH. This is the first study to link microbiology data with hospital admissions and 
to quantify this reduction in PICUs, though such changes are well recognised by clinicians 
[20]. 
Although there is broad recognition of the importance of risk-adjustment, current PICU risk-
adjustment scores for mortality (PIM2) or indicators of severity of illness (renal support, 
mechanical ventilation) do not accurately capture all risk-factors for BSI. There was no 
evidence of differing rates of PICU-acquired BSI due to skin organisms between units, 
suggesting that variation in rates of pathogens may be due to differences in PICU casemix 
that are not routinely captured. More detailed risk-factor information may further explain 
variation between PICUs and improvements in routine data quality and methodology will 
allow a wider range of risk-factors to be explored. Use of information on trajectories of care 
preceding PICU admission using longitudinal hospital administrative data may enhance risk-
adjustment [21-24]. 
We identified large differences between rates of total BSI and clinically significant BSI for 
both skin and non-skin organisms. Although definitions for classification of healthcare-
associated BSI exist, there are no clear criteria to guide clinical judgement on classification of 
clinically significant positive isolates that are reported to the national surveillance system 
LabBase2 [25-27]. Clinicians need to make daily judgements for the care and treatment of 
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patients, but national monitoring requires objective outcome measures to achieve fair 
comparisons. Automated downloads of laboratory data to the voluntary surveillance system, 
introduced in recent years, offer the opportunity to capture all positive BSI data. Analysis 
based on these data would overestimate the total burden of clinically significant BSI acquired 
in PICU, as in our study. However, it is also important to monitor contamination, as this may 
lead to overtreatment and possible increased length of stay in PICU.  Measuring all positive 
BSI would ensure valid comparisons, undistorted by variations in clinical opinion on clinical 
significance.   
The success of risk-adjusted monitoring on a national scale will depend on a linkage 
infrastructure that ensures data quality and minimises error due to linkage of imperfect or 
incomplete identifiers, while allowing for standardised, risk-adjusted analyses of infection 
rates. Our analyses quantify substantial reductions in BSI rates in two PICUS, but a national 
system is required to identify units where further improvements are needed and to determine 
which practice innovations have most impact. 
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TABLES 
Table 1: PICANet data: characteristics of all children admitted to two PICUs in England, 2003-2010 
  N admissions  % 
Length of stay <48 hours 9059 43.29 
 >=48 hours 11865 56.71 
Year of admission 2003 2361 11.28 
 2004 2762 13.20 
 2005 2423 11.58 
 2006 2647 12.65 
 2007 2638 12.61 
 2008 2664 12.73 
 2009 2936 14.03 
 2010 2493 11.91 
Quarter of year Jan-Mar 4833 23.10 
 Apr-Jun 5425 25.93 
 Jul-Sep 5564 26.59 
 Oct-Dec 5102 24.38 
PICU PICU 1 12310 58.83 
 PICU 2 8614 41.17 
Admission type Planned 8583 41.02 
 Unplanned 12341 58.98 
Admission source Same hospital 12772 61.04 
 Elsewhere 8152 38.96 
Diagnosis Group Other 7163 34.23 
 Cardiovascular 8493 40.59 
 Respiratory 4600 21.98 
 Infection 668 3.19 
Renal support  No 20081 95.97 
 Yes 843 4.03 
Mechanical 
ventilation 
No 16195 77.4 
 Yes 4729 22.6 
Sex Female 11813 56.46 
 Male 9110 43.54 
 Unknown 1 0.00 
Age group <1 year 11347 54.23 
 1-4 years 4839 23.13 
 5-10 years 2611 12.48 
 11-15 years 2127 10.17 
Total  20924  
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Table 2: Rate and risk-adjusted incidence rate ratios (IRRs) for PICU-acquired BSI. IRRs were adjusted 
for all significant risk-factors listed in the table and the IRR for year of admission was converted from the 
IRR for quarter-year of admission.  
 
 PICU-acquired BSI 
Rate (95% CI) per 1000 bed-days  15.17 (14.45-15.86)  
% (95% CI) of admissions with 
BSI 
 6.82% (6.48%-7.17%)  
  
N episodes  
Incidence rate ratio (95% 
CI) 
p-value 
Year of admission  0.91 (0.89-0.93) <0.001 
Quarter of year    
Jan-Mar 472 1  
Apr-June 429 0.83 (0.73-0.95)  
Jul-Sep 410 0.83 (0.73-0.95)  
Oct-Dec  450 0.96 (0.85-1.10) 0.005 
Age (months)  0.99 (0.99-0.99) <0.001 
PICU    
PICU 1 976 1  
PICU 2 785 1.26 (1.14-1.39) <0.001 
Admission type    
Planned 448 1  
Unplanned 1313 1.45 (1.28-1.64) 0.001 
Admission source    
Same hospital 1007 1  
Elsewhere  754 0.72 (0.65-0.80) <0.001 
Diagnosis group    
Other 632 1  
Cardiovascular 601 0.81 (0.72-0.92)  
Respiratory 441 0.77 (0.68-0.87)  
Infection 87 1.26 (1.01-1.59) <0.001 
Renal support    
No 1482 1  
Yes 279 1.47 (1.29-1.68) <0.001 
Total 1761   
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Table 3: Rates and risk-adjusted incidence rate ratios (IRRs) of PICU-acquired BSI due to skin 
organisms and non-skin organisms. IRRs were adjusted for all significant risk-factors listed in the table.  
 
 Skin organisms Non-skin organisms 
Rate (95% CI)        per 
1000 bed-days  
 9.29 (8.74-9.84)   7.37 (6.86-7.85)  
% (95% CI)             of 
admissions with >=1 
specimen 
 4.62% (4.34%-4.92%)   
3.06% (2.83%-
3.30%) 
 
  
n 
Incidence rate ratio 
(95% CI) 
p-value n 
Incidence rate ratio 
(95% CI) 
p-value 
Year   0.90 (0.87-0.93) <0.001  0.92 (0.89-0.94) <0.001 
Quarter       
Jan-Mar 290 1  227   
Apr-June 266 0.83 (0.71-0.99)  212 Not significant 0.230 
Jul-Sep 250 0.82 (0.69-0.97)  200   
Oct-Dec  272 0.96 (0.81-1.14) 0.0457 216   
Age (months)  0.99 (0.99-0.99) <0.001  0.99 (0.99-0.99) <0.001 
Admission source       
Same hospital 595 1  513 1  
Elsewhere 483 0.75 (0.66-0.86) <0.001 342 0.70 (0.60-0.81) <0.001 
PICU         
PICU 1 633 1   436 1   
PICU 2 445 1.10 (0.97-1.25) 0.134 419 1.51 (1.31-1.74) <0.001 
Admission type       
Planned 272 1  229 1  
Unplanned 806 1.39 (1.20-1.63) <0.001 626 1.25 (1.04-1.51) 0.015 
Diagnosis group         
Other 406 1   289 1   
Cardiovascular 338 0.70 (0.60-0.81)  310 0.87 (0.73-1.04)  
Respiratory 301 0.81 (0.70-0.94)  195 0.75 (0.62-0.90)  
Infection 33 0.75 (0.52-1.07) <0.001 61 2.00 (1.52-2.66) <0.001 
Renal support       
No 921 1  709 1  
Yes 157 1.42 (1.19-1.68) <0.001 146 1.53 (1.28-1.84) 0.001 
Mechanical Ventilation       
Yes 192 Not significant  180 1  
No 886   675 0.75 (0.63-0.90) 0.002 
PIM2  Not significant   1.67 (1.08-2.57) 0.021 
Total 1078     855     
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FIGURES 
 
Fig. 1 Probability of remaining free from PICU-acquired BSI in first 60 days of admission by PICU, 
adjusted for mechanical ventilation, age, PIM2, renal status, admission type, admission source, diagnosis 
group and quarter-year at admission. 
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Fig. 2 Rates of PICU-acquired BSI due to skin organisms and non-skin organisms by PICU and quarter-
year at admission, adjusted for quarter of year, admission type, admission source, age, renal support and 
diagnosis group. Symbols = Quarterly crude rates; Lines=Kernel density estimate of risk-adjusted trends 
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Fig. 3 Rates of clinically significant and all PICU-acquired BSI at PICU 2 by quarter-year at admission, 
adjusted for quarter of year, admission type, admission source, age, renal support and diagnosis group. 
Symbols = Quarterly crude rates; Lines=Kernel density estimate of risk-adjusted rates 
 
 
 
